Pre-Filled Syringes: World Market Prospects 2012-2022
Report Details
Your guide to trends and sales potential for prefillable syringe products
What are the commercial prospects for pre-filled syringes and related technologies? Visiongain's report shows you potential revenues and other trends to 2022, discussing data, opportunities and prospects.
Our new study analyses those parenteral devices and their therapeutic applications. You find projected sales to 2022 at overall world market, submarket, injected drug and national level.
In addition to an overall world revenue forecast for pre-filled syringe products, you see forecasting of world-level submarkets to 2022:
Leading national markets analysed
In our study you find revenue forecasts for nine leading national markets to 2022:
What issues decide the future of the industry and market?
Our study lets you assess industry trends and outlooks. You find discussions of many issues and developments, including R&D:
You discover prospects for applications of prefillable syringe technologies
Our report also analyses applications of pre-filled drug delivery technologies - medical products. You discover world-level revenue forecasting for nine drug classes to 2022:
Market size and growth prospects
What does the future hold? Overall revenues from pre-filled syringes will rise from 2012 to 2022, our report forecasts. Improved drug delivery and new formulations will be vital to pharmaceutical companies, increasing demand for medical injection devices.
In 2011, 2.45 billion of those syringe units sold. Our study predicts unit sales of 3.59 billion in 2015. Pre-filled syringes form one of the fastest growing markets in healthcare.
Safety, stability, convenience and cost-effectiveness benefit unit sales and revenues. Our analyses predict strong revenue growth to 2022 for those medical devices and their applications in human therapy.
Discover profiles for leading companies
What are syringe companies doing? Our work profiles leading companies, assessing their technologies and products. You see activities and outlooks for developers and producers:
You find commercial news, developmental trends, market shares and sales forecasting
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles, R&D and commercial developments. You receive 90 tables, 54 charts and six research interviews.
Nine ways Pre-Filled Syringes: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
Gain research and analysis for pre-filled syringes and related drug delivery now
Our study is for everybody needing industry and market analyses for pre-filled syringes and related technologies. You find data, trends and predictions there. Please order that report now.
Your guide to trends and sales potential for prefillable syringe products
What are the commercial prospects for pre-filled syringes and related technologies? Visiongain's report shows you potential revenues and other trends to 2022, discussing data, opportunities and prospects.
Our new study analyses those parenteral devices and their therapeutic applications. You find projected sales to 2022 at overall world market, submarket, injected drug and national level.
In addition to an overall world revenue forecast for pre-filled syringe products, you see forecasting of world-level submarkets to 2022:
- Pre-filled syringes
- Pen systems and autoinjectors.
Leading national markets analysed
In our study you find revenue forecasts for nine leading national markets to 2022:
- The US
- Japan
- Germany, France, the UK, Spain and Italy (EU5 countries)
- China
- India.
What issues decide the future of the industry and market?
Our study lets you assess industry trends and outlooks. You find discussions of many issues and developments, including R&D:
- Cost savings and efficiencies
- Plastic disposable syringes and components
- Glass single-use syringes and related parts
- Syringe technology, needles, materials and compound stability
- Safety and convenience issues for the injection devices
- Product differentiation and customisation
- Reimbursement and legislation.
You discover prospects for applications of prefillable syringe technologies
Our report also analyses applications of pre-filled drug delivery technologies - medical products. You discover world-level revenue forecasting for nine drug classes to 2022:
- Monoclonal antibodies (MAbs)
- Insulins
- Erythropoietins
- Interferons
- G-CSF agents
- Recombinant coagulations factors
- Other therapeutic proteins
- Biosimilars and follow-on protein products
- Vaccines.
Market size and growth prospects
What does the future hold? Overall revenues from pre-filled syringes will rise from 2012 to 2022, our report forecasts. Improved drug delivery and new formulations will be vital to pharmaceutical companies, increasing demand for medical injection devices.
In 2011, 2.45 billion of those syringe units sold. Our study predicts unit sales of 3.59 billion in 2015. Pre-filled syringes form one of the fastest growing markets in healthcare.
Safety, stability, convenience and cost-effectiveness benefit unit sales and revenues. Our analyses predict strong revenue growth to 2022 for those medical devices and their applications in human therapy.
Discover profiles for leading companies
What are syringe companies doing? Our work profiles leading companies, assessing their technologies and products. You see activities and outlooks for developers and producers:
- Becton, Dickinson and Company (BD)
- Vetter Pharma-Fertigung
- SCHOTT
- Abbott Laboratories
- Ypsomed
- Gerresheimer
- MGlas
- Unilife.
You find commercial news, developmental trends, market shares and sales forecasting
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles, R&D and commercial developments. You receive 90 tables, 54 charts and six research interviews.
Nine ways Pre-Filled Syringes: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
- Find potential revenues to 2022 for the overall world market and submarkets
- Discover forecasted revenue trends of applications - 9 drug classes to 2022
- Find projected revenues of 14 leading therapeutic products to 2022
- See market forecasting to 2022 for the US, Japan, 5 leading EU countries, China and India
- Assess 8 leading companies, and other players, discovering activities and outlooks
- Investigate competition and opportunities influencing sales
- Find out what will stimulate and restrain the industry and market
- Analyse prospects for established companies and those seeking to enter the sector
- View opinions from our survey, seeing interviews with authorities.
Gain research and analysis for pre-filled syringes and related drug delivery now
Our study is for everybody needing industry and market analyses for pre-filled syringes and related technologies. You find data, trends and predictions there. Please order that report now.
1. EXECUTIVE SUMMARY
1.1 Pre-Filled Syringes Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. INTRODUCTION TO PRE-FILLED SYRINGES
2.1 The Pre-Filled Syringe Market
2.1.1 Market Overview
2.1.2 An Increasingly Alluring Sector
2.1.3 Greater Prevalence of Pre-Filled Syringes
2.1.4 Pre-Filled Syringes: The Current Situation
2.2 Introduction to Syringe Technology
2.2.1 A Brief Historical Perspective
2.3 The Design and Construction of Pre-Filled Syringes
2.3.1 Pre-Filled Syringe Components
2.3.2 Silicone and Biotechnology Products
2.3.3 Material Choice: Will Plastic Predominate?
2.3.4 Manual and Mechanical Syringe Operation
2.3.5 The Challenge of Extractables, Leachables and Residuals
2.3.6 Pre-Filled Syringes: Testing Requirements of the Delivery Systems
2.4 Pre-Filled Syringes Offer Convenience over Alternatives
2.4.1 Pre-Filled Syringes for Lyophilized Drugs
2.5 Needle Stick Injuries and the Drive Towards Pre-Filled Syringes
2.5.1 Blood-Borne Pathogens and Needle Stick Injury
2.5.2 Accidental Needle Stick Injuries: a Serious Healthcare Issue
2.6 Injection Delivery Devices
2.6.1 Pen Injectors
2.6.2 Insulin Pens
2.6.3 Auto-Injectors
2.6.4 Needle-Free Injectors
2.6.5 Selection of Injection Devices
3. THE WORLD PRE-FILLED SYRINGES TECHNOLOGY MARKET, 2012-2022
3.1 The World Pre-Filled Syringes Market in 2011
3.2 Growing Market for Pre-Filled Syringes
3.2.1 Sales Forecast for Pre-Filled Syringe Units, 2011-2016
3.2.2 Sales Forecast for Pre-Filled Syringe Units, 2017-2022
3.2.3 Sales Forecast for Pen Systems & Autoinjectors Market, 2011-2016
3.2.4 Sales Forecast for Pen Systems & Autoinjectors Market, 2017-2022
3.2.5 Sales Forecast for Other Pre-Filled Syringe Systems Market, 2011-2016
3.2.6 Sales Forecast for Other Pre-Filled Syringe Systems Market, 2017-2022
3.2.7 Sales Forecast for Overall Pre-Filled Syringes Market, 2011-2016
3.2.8 Sales Forecast for Overall Pre-Filled Syringes Market, 2017-2022
3.2.9 Summary: World Pre-Filled Syringes Market, 2011-2022
3.3 Leading National Markets for Pre-Filled Syringes, 2011-2022
3.3.1 The US Pre-Filled Syringe Market, 2011-2022
3.3.2 The Japanese Pre-Filled Syringe Market, 2011-2022
3.3.3 The Leading European Pre-Filled Syringe Markets, 2011-2022
3.3.4 Emerging-Economy Pre-Filled Syringe Markets
3.3.5 The Chinese Pre-Filled Syringe Market, 2011-2022
3.3.6 The Indian Pre-Filled Syringe Market, 2011-2022
3.4 Summary of National Market Forecasts
4. APPLICATIONS FOR PRE-FILLED SYRINGES AND RELATED TECHNOLOGY TO 2022
4.1 Therapeutic Areas Offering Growth Opportunities
4.2 Development of Biologics and Vaccines Will Drive the Pre-Filled Syringes Market from 2012-2022
4.3 The Leading Sectors of Biological Drugs Market, 2011
4.3.1 Monoclonal Antibodies Currently Lead the Biologics Market
4.3.1.1 Long-Term Prospects for Monoclonal Antibodies and Implications for the Pre-Filled Syringes Market
4.3.2 The Human Insulins Class Will Exhibit Strong Growth
4.3.3 Erythropoietin Products - How Will Reported Safety Affect Sales?
4.3.3.1 Erythropoietin Products Forecast, 2012-2022
4.3.4 The Interferons Class will Show an Increase in Revenues from 2012-2016
4.3.4.1 Long-Term Forecast for the Interferons Class
4.3.5 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2012-2022
4.3.6 Recombinant Coagulation Factors Will Show Steady Growth
4.3.7 Other Therapeutic Proteins
4.3.8 The Biosimilars Market, 2011
4.3.8.1 Forecast for the World Biosimilars Market, 2012-2022
4.3.9 Forecast for the Vaccines Market, 2012-2022
4.4 The Pre-Filled Syringe Drug Market: Conclusions
5. LEADING PRE-FILLED SYRINGE PRODUCTS, 2012-2022
5.1 Introduction
5.2 Insulins and Antidiabetic Agents
5.2.1 Leading Human Insulins and Analogues
5.2.1.1 Lantus
5.2.1.2 Humalog
5.2.1.3 NovoRapid
5.2.1.4 NovoMix/NovoLog
5.2.1.5 Levemir
5.2.1.6 Actraphane HM
5.3 Byetta/Exenatide LAR
5.3.1 Byetta's Strengths
5.3.2 Restraints on Byetta
5.3.3 Eli Lilly and Amylin Agree to Terminate Collaborative Alliance: Byetta Responsibility Moves to Amylin
5.4 Leading Biotech Products in Pre-Filled Syringe Format
5.4.1 Humira
5.4.1.1 Humira - 2011's Leading Biotech Drug
5.4.1.2 Humira Market Forecast, 2012-2022
5.4.1.3 Long-Term Prospects for Humira
5.4.2 Enbrel
5.4.2.1 Amgen Continues to Benefit from Enbrel Sales
5.4.2.2 Enbrel Sales Will Show an Initial Increase
5.4.2.3 Study Eases Fears of TNF Blocker Cancer Risk
5.4.2.4 New Enbrel Delivery System
5.4.2.5 Enbrel Lifecycle Management
5.4.2.6 Sales of Enbrel will Eventually Decline
5.4.2.7 Enbrel Faces Competition from Several Other Biotech Drugs
5.4.2.8 Competition from Biosimilars?
5.4.3 Neulasta
5.4.3.1 Neulasta Sales Forecast, 2012-2022
5.5 Other Pre-Filled Drugs on the Market
5.5.1 Avonex
5.5.1.1 Avonex Market Forecast, 2012-2022
5.5.1.2 Avonex Faces Competition from New Oral MS Drugs
5.5.2 Rebif
5.5.2.1 Rebiject II
5.5.2.2 RebiSmart
5.5.2.3 Rebif Sales Forecast, 2011-2016
5.5.2.4 Rebif Sales Forecast, 2017-2022
5.5.3 Copaxone
5.5.3.1 Copaxone Sales Forecast 2012-2022
5.5.3.2 Copaxone Will Benefit from Label Extension
5.5.3.3 Threat from Generic Competition
5.5.4 Cimzia
5.5.4.1 Cimzia Sales Forecast 2012-2022
5.5.5 Leading Pre-Filled Vaccine Products, 2012
6. LEADING COMPANIES IN THE PRE-FILLED SYRINGE FIELD, 2012
6.1 Introduction
6.2 Becton, Dickinson and Company (BD)
6.2.1 Overview
6.2.2 Global Presence
6.2.3 Distribution
6.2.4 Focus on Parenteral and Biomaterial Technologies
6.2.5 Products
6.2.5.1 BD Hypak SCF Syringe Systems
6.2.5.2 BD Sterifill SCF Syringe Systems
6.2.5.3 Self-Injection Systems
6.2.5.3.1 BD Physioject Disposable AutoInjector
6.2.5.3.2 BD MicroInfusor Automatic Injection System
6.2.5.3.3 BD Liquid Dry Injector Disposable Pen Injector
6.2.5.3.4 BD Pens
6.2.5.4 Detachable and Integrated Safety Systems
6.2.5.5 BD Soluvia Pre-Fillable Microinjection System
6.2.5.6 BD Uniject SCF: Auto-Disable Injection System
6.2.6 R&D
6.2.7 Revenues
6.3 Vetter Pharma-Fertigung
6.3.1 Overview
6.3.2 Global Presence
6.3.3 Business Interests
6.3.3.1 Vetter Development Service
6.3.3.2 Vetter Commercial Manufacturing
6.3.3.3 Vetter Solutions
6.3.4 Capabilities
6.3.5 R&D
6.3.6 Product Focus
6.3.6.1 Dual-Chamber Technology
6.3.6.2 Single-Chamber Syringes and Cartridges
6.3.7 Future Outlook
6.4 SCHOTT
6.4.1 Overview
6.4.2 Global Presence
6.4.3 SCHOTT's Pharmaceutical Systems
6.4.4 SCHOTT's Pharmaceutical Packaging Business Segment
6.4.5 Products: Pre-Fillable Polymer Syringes
6.4.5.1 SCHOTT TopPac Pre-Fillable Syringes
6.4.5.2 SCHOTT InJentle: Innovative Staked Needle Syringe
6.4.6 Revenues
6.5 Abbott Laboratories
6.5.1 Overview
6.5.2 Market Areas and Products
6.5.3 Pre-Filled Syringe Products: Humira
6.5.4 Abbott's Other Syringe Products
6.5.4.1 Abbott Abboject
6.5.4.2 Abbott LifeShield
6.5.4.3 Abbott Ansyr
6.5.4.4 Abbott Carpuject Injector
6.5.5 Revenues and Growth
6.6 Ypsomed
6.6.1 Overview
6.6.2 Global Presence
6.6.3 Products
6.6.3.1 Insulin Pen Injectors
6.6.3.2 Pen Injectors for Other Indications
6.6.3.3 Monodose Pens for Dual-Chamber Cartridges
6.6.3.4 Disposable Auto-Injectors
6.6.3.5 Standard Pen Needles Penfine and Clickfine
6.6.3.6 Safety Pen Needle Clickfine AutoProtect
6.6.4 R&D
6.6.5 Revenues and Growth
6.6.6 Future Outlook
6.7 Gerresheimer
6.7.1 Overview
6.7.2 Business Operations
6.7.3 Locations
6.7.4 Gerresheiemer's Tubular Glass Division
6.7.5 Syringe Systems
6.7.5.1 Technology Centre for Syringe Systems
6.7.5.2 Technical Competence Centre for Plastic Products
6.7.6 Revenues
6.7.7 R&D
6.7.8 Outlook
6.8 MGlas (MG)
6.8.1 Overview
6.8.2 Products
6.8.2.1 Pre-Fillable Syringes/Cartridges/Vials
6.8.2.2 MG Innovative Needles
6.9 Unilife
6.9.1 Overview
6.9.2 Products and Services
6.9.3 Unifill Select and EZMix Multi-Chamber Syringes
6.9.4 Unifill Auto-Injectors
6.9.5 AutoInfusors
6.9.6 Unitract Safety Syringe Technology
6.9.7 Revenues
6.9.8 Future Outlook
6.10 Companies Providing Aseptic Pre-Filled Syringes/Sterile Syringe Filling Services
6.11 Companies Providing Syringe Filling Machines and Related Equipment
7. ANALYSIS OF FORCES INFLUENCING THE PRE-FILLED SYRINGES INDUSTRY AND MARKET
7.1 Introduction
7.2 Commercial Drivers of the Pre-Filled Syringes Market
7.2.1 Cost Savings - a Powerful Motivator?
7.2.2 Glass Pre-Fillable Syringes
7.2.3 Plastic Pre-Fillable Syringes
7.2.4 Convenience and Safety Issues
7.2.5 Cost Efficiencies
7.2.6 Product Differentiation and Customisation
7.2.7 Reimbursement
7.3 Commercial Restraints for the Pre-Filled Syringes Market
7.3.1 Pre-Filled Syringe Systems Have Limitations
7.3.2 Patients Prefer Pills
7.4 Emerging Trends in the Pre-Filled Syringes Industry and Market: Opportunity Analysis
7.5 Challenges Facing the Pre-Filled Syringes Industry and Market
7.5.1 Needle Stick Safety and Prevention Laws
7.5.1.1 Compliance with Needle Stick Safety and Prevention Laws
7.5.1.2 Main Findings Leading to the Legislation
7.5.1.3 Increasing Exposure to Blood-Borne Pathogens
7.5.1.4 OSHA 1991 Regulation Standard
7.5.1.5 Estimated Needle Stick and Other Percutaneous Injuries Occurring Annually in the US
7.5.1.6 Newer Engineering Controls and Safer Medical Devices
7.5.1.7 CDC Estimates 80% of Sharps Injuries Are Preventable
7.5.1.8 OSHA 200 Log Surveillance System
7.5.1.9 Training and Education
7.5.1.10 Summary of Regulatory and Legislative Requirements
7.5.2 State-Level OSHA Plans and Federal Legislation
7.5.3 BPS Enforcement by OSHA
7.5.4 Laws in Other International Markets
7.5.5 The EU and Laws to Tackle Needle Stick Injuries
7.5.6 High Entry Barriers, Few Suppliers
7.5.7 Product Stability a Major Concern
7.5.7.1 Leachables and Safety
7.5.7.2 Compatibility between Drug Product and Pre-Filled Syringes
7.5.7.3 Eprex and Leaching
7.5.7.4 Protein Aggregation Related to Leached Tungsten
7.5.7.5 Protein Aggregation Related to Silicone Oil
7.5.8 Product Stability and Quality Assurance Programme
7.5.8.1 Paediatric H1N1 Vaccine
7.5.8.2 Reported Challenges with Some Flu Vaccine
7.5.8.3 Reported Shelf Life Issues of Some H1N1 Vaccine
7.5.8.4 Contamination Challenges with Leachables
7.5.8.5 West and Daikyo Offer Syringe Systems to Minimise Leaching
7.5.8.6 SCHOTT AG Launched InJentle Syringe to Improve Drug Stability
7.6 Conclusions
8. RESEARCH INTERVIEWS: OPINIONS FROM OUR SURVEY
8.1 Interview 1: Mr Ian Thompson, Vice President Business Development, Delivery Systems, Ypsomed AG, Burgdorf, Switzerland
8.1.1 Current Market Size for Pre-Filled Syringes
8.1.2 Key Unmet Needs
8.1.3 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.1.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.1.5 On Trends in Pre-Filled Syringes and Cartridges
8.1.6 On Ypsomed
8.1.7 On Lyophilised Products and Dual-Chamber Syringes
8.1.8 On Demand and Production Capacity for Pre-Filled Syringes
8.1.9 New Developments and R&D
8.2 Interview 2: Authority from a Company in the Sector (Views Provided Anonymously)
8.2.1 Current Market Size for Pre-Filled Syringes
8.2.2 Key Unmet Needs
8.2.3 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.2.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.2.5 Drawbacks of Pre-Filled Syringes
8.2.6 New Developments and R&D
8.3 Interview 3: Dr Phil Lever, Commercial Director, Cambridge Consultants, Cambridge, UK
8.3.1 Current Market Size for Pre-Filled Syringes
8.3.2 Key Unmet Needs
8.3.3 Research and Development
8.3.4 Challenges with Pre-Filled Syringes
8.3.5 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.3.6 Drawbacks of Pre-Filled Syringes
8.3.7 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.3.8 Complexities for Developing New Pre-Filled Syringes
8.3.9 Preferred Component Materials, Surface Treatments and Filling Processes
8.3.10 Technologies, Developments and R&D
8.3.11 Main Therapeutic Areas Offering Growth Opportunities
8.3.12 The Future of PFS Over the Next 10-15 Years
8.3.13 Main Threats Facing the PFS Industry
8.3.14 Novel Technology/Developments
8.3.15 Potential Replacement
8.4 Interview 4: Authority from a Company in the Sector (Views Provided Anonymously)
8.4.1 Unmet Needs and Market for Pre-Filled Syringes
8.4.2 Competing Products and Alternatives to Pre-Filled Syringes
8.4.3 Disadvantages and Drawbacks of Pre-Filled Syringes and Related Devices
8.4.4 Pre-Filled Syringe Products, Safety and Vaccines
8.4.5 Challenges for Complex Biological Agents in Pre-Filled Syringes
8.4.6 Versatility of Pre-Filled Syringes
8.4.7 Dual-Chamber Pre-Filled Syringe Systems
8.4.8 Syringe Material: Glass vs. Plastic
8.4.9 Future Developments in Pre-Filled Syringe Systems
8.4.10 Progress in Needle Stick Injury (NSI) Legislation for Europe
8.4.11 NSI Legislation and Implications for Stakeholders
8.5 Interview 5: Dr Marja van der Heijden, Pharmaceutical Formulations Scientist, Abbott Healthcare Products B.V., Amsterdam, Netherlands
8.5.1 The Main Unmet Needs
8.5.2 Research and Development
8.5.3 Research Challenges Facing Pre-Filled Syringe Technology
8.5.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.5.5 Drawbacks of Pre-Filled Syringes
8.5.6 Technologies, Developments and R&D
8.6 Interview 6: Mr David Daily, Director for R&D and BD, Injectable Drug Delivery Devices (I3D), Elcam Medical and CEO, DALI Medical Devices, Israel
8.6.1 Current Market Worth for Pre-Filled Syringes
8.6.2 Key Unmet Needs
8.6.3 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.6.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.6.5 On Trends in Pre-Filled Syringes and Cartridges
8.6.6 On Proportion of Vials vs. Pre-Filled Syringes
8.6.7 On Elcam
8.6.8 On Impact of Biologics and Biosimilars
8.6.9 On Demand and Production Capacity for Pre-Filled Syringes
8.6.10 New Developments and R&D
9. CONCLUSIONS FROM OUR RESEARCH AND ANALYSES
9.1 Introduction
9.2 Leading Players in the Market
9.3 Commercial Drivers of the Pre-Filled Syringe Market
9.4 Future Outlook
9.4.1 Further Advances?
9.4.2 Future Developments in Pre-Filled Syringe Systems
9.5 Concluding Remarks
1.1 Pre-Filled Syringes Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. INTRODUCTION TO PRE-FILLED SYRINGES
2.1 The Pre-Filled Syringe Market
2.1.1 Market Overview
2.1.2 An Increasingly Alluring Sector
2.1.3 Greater Prevalence of Pre-Filled Syringes
2.1.4 Pre-Filled Syringes: The Current Situation
2.2 Introduction to Syringe Technology
2.2.1 A Brief Historical Perspective
2.3 The Design and Construction of Pre-Filled Syringes
2.3.1 Pre-Filled Syringe Components
2.3.2 Silicone and Biotechnology Products
2.3.3 Material Choice: Will Plastic Predominate?
2.3.4 Manual and Mechanical Syringe Operation
2.3.5 The Challenge of Extractables, Leachables and Residuals
2.3.6 Pre-Filled Syringes: Testing Requirements of the Delivery Systems
2.4 Pre-Filled Syringes Offer Convenience over Alternatives
2.4.1 Pre-Filled Syringes for Lyophilized Drugs
2.5 Needle Stick Injuries and the Drive Towards Pre-Filled Syringes
2.5.1 Blood-Borne Pathogens and Needle Stick Injury
2.5.2 Accidental Needle Stick Injuries: a Serious Healthcare Issue
2.6 Injection Delivery Devices
2.6.1 Pen Injectors
2.6.2 Insulin Pens
2.6.3 Auto-Injectors
2.6.4 Needle-Free Injectors
2.6.5 Selection of Injection Devices
3. THE WORLD PRE-FILLED SYRINGES TECHNOLOGY MARKET, 2012-2022
3.1 The World Pre-Filled Syringes Market in 2011
3.2 Growing Market for Pre-Filled Syringes
3.2.1 Sales Forecast for Pre-Filled Syringe Units, 2011-2016
3.2.2 Sales Forecast for Pre-Filled Syringe Units, 2017-2022
3.2.3 Sales Forecast for Pen Systems & Autoinjectors Market, 2011-2016
3.2.4 Sales Forecast for Pen Systems & Autoinjectors Market, 2017-2022
3.2.5 Sales Forecast for Other Pre-Filled Syringe Systems Market, 2011-2016
3.2.6 Sales Forecast for Other Pre-Filled Syringe Systems Market, 2017-2022
3.2.7 Sales Forecast for Overall Pre-Filled Syringes Market, 2011-2016
3.2.8 Sales Forecast for Overall Pre-Filled Syringes Market, 2017-2022
3.2.9 Summary: World Pre-Filled Syringes Market, 2011-2022
3.3 Leading National Markets for Pre-Filled Syringes, 2011-2022
3.3.1 The US Pre-Filled Syringe Market, 2011-2022
3.3.2 The Japanese Pre-Filled Syringe Market, 2011-2022
3.3.3 The Leading European Pre-Filled Syringe Markets, 2011-2022
3.3.4 Emerging-Economy Pre-Filled Syringe Markets
3.3.5 The Chinese Pre-Filled Syringe Market, 2011-2022
3.3.6 The Indian Pre-Filled Syringe Market, 2011-2022
3.4 Summary of National Market Forecasts
4. APPLICATIONS FOR PRE-FILLED SYRINGES AND RELATED TECHNOLOGY TO 2022
4.1 Therapeutic Areas Offering Growth Opportunities
4.2 Development of Biologics and Vaccines Will Drive the Pre-Filled Syringes Market from 2012-2022
4.3 The Leading Sectors of Biological Drugs Market, 2011
4.3.1 Monoclonal Antibodies Currently Lead the Biologics Market
4.3.1.1 Long-Term Prospects for Monoclonal Antibodies and Implications for the Pre-Filled Syringes Market
4.3.2 The Human Insulins Class Will Exhibit Strong Growth
4.3.3 Erythropoietin Products - How Will Reported Safety Affect Sales?
4.3.3.1 Erythropoietin Products Forecast, 2012-2022
4.3.4 The Interferons Class will Show an Increase in Revenues from 2012-2016
4.3.4.1 Long-Term Forecast for the Interferons Class
4.3.5 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2012-2022
4.3.6 Recombinant Coagulation Factors Will Show Steady Growth
4.3.7 Other Therapeutic Proteins
4.3.8 The Biosimilars Market, 2011
4.3.8.1 Forecast for the World Biosimilars Market, 2012-2022
4.3.9 Forecast for the Vaccines Market, 2012-2022
4.4 The Pre-Filled Syringe Drug Market: Conclusions
5. LEADING PRE-FILLED SYRINGE PRODUCTS, 2012-2022
5.1 Introduction
5.2 Insulins and Antidiabetic Agents
5.2.1 Leading Human Insulins and Analogues
5.2.1.1 Lantus
5.2.1.2 Humalog
5.2.1.3 NovoRapid
5.2.1.4 NovoMix/NovoLog
5.2.1.5 Levemir
5.2.1.6 Actraphane HM
5.3 Byetta/Exenatide LAR
5.3.1 Byetta's Strengths
5.3.2 Restraints on Byetta
5.3.3 Eli Lilly and Amylin Agree to Terminate Collaborative Alliance: Byetta Responsibility Moves to Amylin
5.4 Leading Biotech Products in Pre-Filled Syringe Format
5.4.1 Humira
5.4.1.1 Humira - 2011's Leading Biotech Drug
5.4.1.2 Humira Market Forecast, 2012-2022
5.4.1.3 Long-Term Prospects for Humira
5.4.2 Enbrel
5.4.2.1 Amgen Continues to Benefit from Enbrel Sales
5.4.2.2 Enbrel Sales Will Show an Initial Increase
5.4.2.3 Study Eases Fears of TNF Blocker Cancer Risk
5.4.2.4 New Enbrel Delivery System
5.4.2.5 Enbrel Lifecycle Management
5.4.2.6 Sales of Enbrel will Eventually Decline
5.4.2.7 Enbrel Faces Competition from Several Other Biotech Drugs
5.4.2.8 Competition from Biosimilars?
5.4.3 Neulasta
5.4.3.1 Neulasta Sales Forecast, 2012-2022
5.5 Other Pre-Filled Drugs on the Market
5.5.1 Avonex
5.5.1.1 Avonex Market Forecast, 2012-2022
5.5.1.2 Avonex Faces Competition from New Oral MS Drugs
5.5.2 Rebif
5.5.2.1 Rebiject II
5.5.2.2 RebiSmart
5.5.2.3 Rebif Sales Forecast, 2011-2016
5.5.2.4 Rebif Sales Forecast, 2017-2022
5.5.3 Copaxone
5.5.3.1 Copaxone Sales Forecast 2012-2022
5.5.3.2 Copaxone Will Benefit from Label Extension
5.5.3.3 Threat from Generic Competition
5.5.4 Cimzia
5.5.4.1 Cimzia Sales Forecast 2012-2022
5.5.5 Leading Pre-Filled Vaccine Products, 2012
6. LEADING COMPANIES IN THE PRE-FILLED SYRINGE FIELD, 2012
6.1 Introduction
6.2 Becton, Dickinson and Company (BD)
6.2.1 Overview
6.2.2 Global Presence
6.2.3 Distribution
6.2.4 Focus on Parenteral and Biomaterial Technologies
6.2.5 Products
6.2.5.1 BD Hypak SCF Syringe Systems
6.2.5.2 BD Sterifill SCF Syringe Systems
6.2.5.3 Self-Injection Systems
6.2.5.3.1 BD Physioject Disposable AutoInjector
6.2.5.3.2 BD MicroInfusor Automatic Injection System
6.2.5.3.3 BD Liquid Dry Injector Disposable Pen Injector
6.2.5.3.4 BD Pens
6.2.5.4 Detachable and Integrated Safety Systems
6.2.5.5 BD Soluvia Pre-Fillable Microinjection System
6.2.5.6 BD Uniject SCF: Auto-Disable Injection System
6.2.6 R&D
6.2.7 Revenues
6.3 Vetter Pharma-Fertigung
6.3.1 Overview
6.3.2 Global Presence
6.3.3 Business Interests
6.3.3.1 Vetter Development Service
6.3.3.2 Vetter Commercial Manufacturing
6.3.3.3 Vetter Solutions
6.3.4 Capabilities
6.3.5 R&D
6.3.6 Product Focus
6.3.6.1 Dual-Chamber Technology
6.3.6.2 Single-Chamber Syringes and Cartridges
6.3.7 Future Outlook
6.4 SCHOTT
6.4.1 Overview
6.4.2 Global Presence
6.4.3 SCHOTT's Pharmaceutical Systems
6.4.4 SCHOTT's Pharmaceutical Packaging Business Segment
6.4.5 Products: Pre-Fillable Polymer Syringes
6.4.5.1 SCHOTT TopPac Pre-Fillable Syringes
6.4.5.2 SCHOTT InJentle: Innovative Staked Needle Syringe
6.4.6 Revenues
6.5 Abbott Laboratories
6.5.1 Overview
6.5.2 Market Areas and Products
6.5.3 Pre-Filled Syringe Products: Humira
6.5.4 Abbott's Other Syringe Products
6.5.4.1 Abbott Abboject
6.5.4.2 Abbott LifeShield
6.5.4.3 Abbott Ansyr
6.5.4.4 Abbott Carpuject Injector
6.5.5 Revenues and Growth
6.6 Ypsomed
6.6.1 Overview
6.6.2 Global Presence
6.6.3 Products
6.6.3.1 Insulin Pen Injectors
6.6.3.2 Pen Injectors for Other Indications
6.6.3.3 Monodose Pens for Dual-Chamber Cartridges
6.6.3.4 Disposable Auto-Injectors
6.6.3.5 Standard Pen Needles Penfine and Clickfine
6.6.3.6 Safety Pen Needle Clickfine AutoProtect
6.6.4 R&D
6.6.5 Revenues and Growth
6.6.6 Future Outlook
6.7 Gerresheimer
6.7.1 Overview
6.7.2 Business Operations
6.7.3 Locations
6.7.4 Gerresheiemer's Tubular Glass Division
6.7.5 Syringe Systems
6.7.5.1 Technology Centre for Syringe Systems
6.7.5.2 Technical Competence Centre for Plastic Products
6.7.6 Revenues
6.7.7 R&D
6.7.8 Outlook
6.8 MGlas (MG)
6.8.1 Overview
6.8.2 Products
6.8.2.1 Pre-Fillable Syringes/Cartridges/Vials
6.8.2.2 MG Innovative Needles
6.9 Unilife
6.9.1 Overview
6.9.2 Products and Services
6.9.3 Unifill Select and EZMix Multi-Chamber Syringes
6.9.4 Unifill Auto-Injectors
6.9.5 AutoInfusors
6.9.6 Unitract Safety Syringe Technology
6.9.7 Revenues
6.9.8 Future Outlook
6.10 Companies Providing Aseptic Pre-Filled Syringes/Sterile Syringe Filling Services
6.11 Companies Providing Syringe Filling Machines and Related Equipment
7. ANALYSIS OF FORCES INFLUENCING THE PRE-FILLED SYRINGES INDUSTRY AND MARKET
7.1 Introduction
7.2 Commercial Drivers of the Pre-Filled Syringes Market
7.2.1 Cost Savings - a Powerful Motivator?
7.2.2 Glass Pre-Fillable Syringes
7.2.3 Plastic Pre-Fillable Syringes
7.2.4 Convenience and Safety Issues
7.2.5 Cost Efficiencies
7.2.6 Product Differentiation and Customisation
7.2.7 Reimbursement
7.3 Commercial Restraints for the Pre-Filled Syringes Market
7.3.1 Pre-Filled Syringe Systems Have Limitations
7.3.2 Patients Prefer Pills
7.4 Emerging Trends in the Pre-Filled Syringes Industry and Market: Opportunity Analysis
7.5 Challenges Facing the Pre-Filled Syringes Industry and Market
7.5.1 Needle Stick Safety and Prevention Laws
7.5.1.1 Compliance with Needle Stick Safety and Prevention Laws
7.5.1.2 Main Findings Leading to the Legislation
7.5.1.3 Increasing Exposure to Blood-Borne Pathogens
7.5.1.4 OSHA 1991 Regulation Standard
7.5.1.5 Estimated Needle Stick and Other Percutaneous Injuries Occurring Annually in the US
7.5.1.6 Newer Engineering Controls and Safer Medical Devices
7.5.1.7 CDC Estimates 80% of Sharps Injuries Are Preventable
7.5.1.8 OSHA 200 Log Surveillance System
7.5.1.9 Training and Education
7.5.1.10 Summary of Regulatory and Legislative Requirements
7.5.2 State-Level OSHA Plans and Federal Legislation
7.5.3 BPS Enforcement by OSHA
7.5.4 Laws in Other International Markets
7.5.5 The EU and Laws to Tackle Needle Stick Injuries
7.5.6 High Entry Barriers, Few Suppliers
7.5.7 Product Stability a Major Concern
7.5.7.1 Leachables and Safety
7.5.7.2 Compatibility between Drug Product and Pre-Filled Syringes
7.5.7.3 Eprex and Leaching
7.5.7.4 Protein Aggregation Related to Leached Tungsten
7.5.7.5 Protein Aggregation Related to Silicone Oil
7.5.8 Product Stability and Quality Assurance Programme
7.5.8.1 Paediatric H1N1 Vaccine
7.5.8.2 Reported Challenges with Some Flu Vaccine
7.5.8.3 Reported Shelf Life Issues of Some H1N1 Vaccine
7.5.8.4 Contamination Challenges with Leachables
7.5.8.5 West and Daikyo Offer Syringe Systems to Minimise Leaching
7.5.8.6 SCHOTT AG Launched InJentle Syringe to Improve Drug Stability
7.6 Conclusions
8. RESEARCH INTERVIEWS: OPINIONS FROM OUR SURVEY
8.1 Interview 1: Mr Ian Thompson, Vice President Business Development, Delivery Systems, Ypsomed AG, Burgdorf, Switzerland
8.1.1 Current Market Size for Pre-Filled Syringes
8.1.2 Key Unmet Needs
8.1.3 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.1.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.1.5 On Trends in Pre-Filled Syringes and Cartridges
8.1.6 On Ypsomed
8.1.7 On Lyophilised Products and Dual-Chamber Syringes
8.1.8 On Demand and Production Capacity for Pre-Filled Syringes
8.1.9 New Developments and R&D
8.2 Interview 2: Authority from a Company in the Sector (Views Provided Anonymously)
8.2.1 Current Market Size for Pre-Filled Syringes
8.2.2 Key Unmet Needs
8.2.3 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.2.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.2.5 Drawbacks of Pre-Filled Syringes
8.2.6 New Developments and R&D
8.3 Interview 3: Dr Phil Lever, Commercial Director, Cambridge Consultants, Cambridge, UK
8.3.1 Current Market Size for Pre-Filled Syringes
8.3.2 Key Unmet Needs
8.3.3 Research and Development
8.3.4 Challenges with Pre-Filled Syringes
8.3.5 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.3.6 Drawbacks of Pre-Filled Syringes
8.3.7 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.3.8 Complexities for Developing New Pre-Filled Syringes
8.3.9 Preferred Component Materials, Surface Treatments and Filling Processes
8.3.10 Technologies, Developments and R&D
8.3.11 Main Therapeutic Areas Offering Growth Opportunities
8.3.12 The Future of PFS Over the Next 10-15 Years
8.3.13 Main Threats Facing the PFS Industry
8.3.14 Novel Technology/Developments
8.3.15 Potential Replacement
8.4 Interview 4: Authority from a Company in the Sector (Views Provided Anonymously)
8.4.1 Unmet Needs and Market for Pre-Filled Syringes
8.4.2 Competing Products and Alternatives to Pre-Filled Syringes
8.4.3 Disadvantages and Drawbacks of Pre-Filled Syringes and Related Devices
8.4.4 Pre-Filled Syringe Products, Safety and Vaccines
8.4.5 Challenges for Complex Biological Agents in Pre-Filled Syringes
8.4.6 Versatility of Pre-Filled Syringes
8.4.7 Dual-Chamber Pre-Filled Syringe Systems
8.4.8 Syringe Material: Glass vs. Plastic
8.4.9 Future Developments in Pre-Filled Syringe Systems
8.4.10 Progress in Needle Stick Injury (NSI) Legislation for Europe
8.4.11 NSI Legislation and Implications for Stakeholders
8.5 Interview 5: Dr Marja van der Heijden, Pharmaceutical Formulations Scientist, Abbott Healthcare Products B.V., Amsterdam, Netherlands
8.5.1 The Main Unmet Needs
8.5.2 Research and Development
8.5.3 Research Challenges Facing Pre-Filled Syringe Technology
8.5.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.5.5 Drawbacks of Pre-Filled Syringes
8.5.6 Technologies, Developments and R&D
8.6 Interview 6: Mr David Daily, Director for R&D and BD, Injectable Drug Delivery Devices (I3D), Elcam Medical and CEO, DALI Medical Devices, Israel
8.6.1 Current Market Worth for Pre-Filled Syringes
8.6.2 Key Unmet Needs
8.6.3 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.6.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.6.5 On Trends in Pre-Filled Syringes and Cartridges
8.6.6 On Proportion of Vials vs. Pre-Filled Syringes
8.6.7 On Elcam
8.6.8 On Impact of Biologics and Biosimilars
8.6.9 On Demand and Production Capacity for Pre-Filled Syringes
8.6.10 New Developments and R&D
9. CONCLUSIONS FROM OUR RESEARCH AND ANALYSES
9.1 Introduction
9.2 Leading Players in the Market
9.3 Commercial Drivers of the Pre-Filled Syringe Market
9.4 Future Outlook
9.4.1 Further Advances?
9.4.2 Future Developments in Pre-Filled Syringe Systems
9.5 Concluding Remarks
LIST OF TABLES
Table 2.1 Summary of Drivers for Growth in the Pre-Filled Syringes Market, 2012
Table 2.2 Historical Timeline for Development of Syringe Technology
Table 2.3 Components of Pre-Fillable Syringes
Table 2.4 Leading Brands of Insulin in Pen Syringe Format, 2012
Table 2.5 Main Factors Increasing the Interest in Auto-Injectors, 2012
Table 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2011-2016
Table 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2017-2022
Table 3.3 Pen Systems & Autoinjectors: World Revenue Forecast, 2011-2016
Table 3.4 Pen Systems & Autoinjectors: World Revenue Forecast, 2017-2022
Table 3.5 Other Pre-Filled Syringes: World Revenue Forecast, 2011-2016
Table 3.6 Other Pre-Filled Syringes: World Revenue Forecast, 2017-2022
Table 3.7 Overall World Pre-Filled Syringe Revenue Forecast, 2011-2016
Table 3.8 Overall World Pre-Filled Syringe Revenue Forecast, 2017-2022
Table 3.9 Pre-Filled Syringe Submarkets: World Revenue Forecasts, 2011-2016
Table 3.10 Pre-Filled Syringe Submarkets: World Revenue Forecasts, 2017-2022
Table 3.11 Leading Pre-Filled Syringe National Revenue Forecasts, 2011-2022
Table 4.1 Leading Product Classes Driving the Pre-Filled Syringes Market, 2011
Table 4.2 Some Currently Marketed Monoclonal Antibodies, 2012
Table 4.3 Monoclonal Antibodies Market: World Revenue Forecast, 2011-2016
Table 4.4 Monoclonal Antibodies Market: World Revenue Forecast, 2017-2022
Table 4.5 Insulins Market: World Revenue Forecast, 2011-2016
Table 4.6 Insulins Market: World Revenue Forecast, 2017-2022
Table 4.7 Erythropoietins Market: World Revenue Forecast, 2011-2016
Table 4.8 Erythropoietins Market: World Revenue Forecast, 2017-2022
Table 4.9 Some Currently Marketed Interferon Drugs, 2012
Table 4.10 Interferons Market: World Revenue Forecast, 2011-2016
Table 4.11 Interferons Market: World Revenue Forecast, 2017-2022
Table 4.12 G-CSF Market: World Revenue Forecast, 2011-2016
Table 4.13 G-CSF Market: World Revenue Forecast, 2017-2022
Table 4.14 Some Currently Marketed Recombinant Coagulation Factors, 2012
Table 4.15 Recombinant Coagulations Factors Market: World Revenue Forecast, 2011-2016
Table 4.16 Recombinant Coagulations Factors Market: World Revenue Forecast, 2017-2022
Table 4.17 Some Marketed Human Growth Hormones, 2012
Table 4.18 Some Currently Marketed Pre-Filled Immunosuppressants Products, 2012
Table 4.19 Other Therapeutic Proteins Market: World Revenue Forecast, 2011-2016
Table 4.20 Other Therapeutic Proteins Market: World Revenue Forecast, 2017-2022
Table 4.21 Some Currently Marketed Biosimilar Drugs, 2012
Table 4.22 Biosimilars Market: World Revenue Forecast, 2011-2016
Table 4.23 Biosimilars Market: World Revenue Forecast, 2017-2022
Table 4.24 Some Currently Marketed Vaccines, 2012
Table 4.25 Overall Vaccines Market: World Revenue Forecast, 2011-2016
Table 4.26 Overall Vaccines Market: World Revenue Forecast, 2017-2022
Table 5.1 Anti-Diabetic Agents Available in Pre-Filled Syringe Format, 2012
Table 5.2 Lantus: World Revenue Forecast, 2011-2016
Table 5.3 Lantus: World Revenue Forecast, 2017-2022
Table 5.4 Humalog: World Revenue Forecast, 2011-2016
Table 5.5 Humalog: World Revenue Forecast, 2017-2022
Table 5.6 NovoRapid: World Revenue Forecast, 2011-2016
Table 5.7 NovoRapid: World Revenue Forecast, 2017-2022
Table 5.8 NovoMix/NovoLog: World Revenue Forecast, 2011-2016
Table 5.9 NovoMix/NovoLog: World Revenue Forecast, 2017-2022
Table 5.10 Levemir: World Revenue Forecast, 2011-2016
Table 5.11 Levemir: World Revenue Forecast, 2017-2022
Table 5.12 Actraphane HM: World Revenue Forecast, 2011-2016
Table 5.13 Actraphane HM: World Revenue Forecast, 2017-2022
Table 5.14 Byetta: World Revenue Forecast, 2011-2016
Table 5.15 Byetta: World Revenue Forecast, 2017-2022
Table 5.16 Humira: World Revenue Forecast, 2011-2016
Table 5.17 Humira: World Revenue Forecast, 2017-2022
Table 5.18 Enbrel: World Revenue Forecast, 2011-2016
Table 5.19 Enbrel: World Revenue Forecast, 2017-2022
Table 5.20 Neulasta: World Revenue Forecast, 2011-2016
Table 5.21 Neulasta: World Revenue Forecast, 2017-2022
Table 5.22 Avonex: World Revenue Forecast, 2011-2016
Table 5.23 Avonex: World Revenue Forecast, 2017-2022
Table 5.24 Rebif: World Revenue Forecast, 2011-2016
Table 5.25 Rebif: World Revenue Forecast, 2017-2022
Table 5.26 Copaxone: World Revenue Forecast, 2011-2016
Table 5.27 Copaxone: World Revenue Forecast, 2017-2022
Table 5.28 Cimzia: World Revenue Forecast, 2011-2016
Table 5.29 Cimzia: World Revenue Forecast, 2017-2022
Table 5.30 Some Leading Pre-Filled Syringe Vaccine Products, 2012
Table 6.1 Leading Companies in the Pre-Filled Syringes Market, 2012
Table 6.2 BD: Company Revenue, 2006-2011
Table 6.3 BD Medical: Revenue by Segment, 2009-2011
Table 6.4 SCHOTT: Revenue 2008-2010
Table 6.5 Ypsomed: Revenue by Segment, 2009-2011
Table 6.6 Ypsomed: Half-Year Revenue by Segment, 2011 & 2012
Table 6.7 Gerresheimer: Revenue by Division, 2009 & 2010
Table 6.8 Unilife: Revenue by Segment, 2009-2011
Table 6.9 Leading Companies Providing Aseptic Pre-Filled Syringes and Sterile Syringe Filling Services, 2012
Table 6.10 Leading Companies Providing Syringe Filling Machines and Related Equipment, 2012
Table 7.1 Pre-Filled Syringes Market: STEP Analysis, 2012-2022
Table 7.2 SWOT Analysis of World Pre-Filled Syringes Market: Strengths, 2012-2022
Table 7.3 SWOT Analysis of World Pre-Filled Syringes Market: Weaknesses, 2012-2022
Table 7.4 SWOT Analysis of World Pre-Filled Syringes Market: Opportunities and Threats, 2012-2022
Table 7.5 Risk of Infection Following Needle Stick Incident, 2012
Table 7.6 Examples of Leachables Impacting on Safety and Product Quality
Table 9.1 Pre-Filled Syringes: World Unit Sales Forecast, 2011, 2013, 2015, 2018, 2020 and 2022
Table 9.2 Pre-Filled Syringes: Overall World Revenue Forecast and Market Breakdown, 2011, 2013, 2015, 2018, 2020 and 2022
Table 2.1 Summary of Drivers for Growth in the Pre-Filled Syringes Market, 2012
Table 2.2 Historical Timeline for Development of Syringe Technology
Table 2.3 Components of Pre-Fillable Syringes
Table 2.4 Leading Brands of Insulin in Pen Syringe Format, 2012
Table 2.5 Main Factors Increasing the Interest in Auto-Injectors, 2012
Table 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2011-2016
Table 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2017-2022
Table 3.3 Pen Systems & Autoinjectors: World Revenue Forecast, 2011-2016
Table 3.4 Pen Systems & Autoinjectors: World Revenue Forecast, 2017-2022
Table 3.5 Other Pre-Filled Syringes: World Revenue Forecast, 2011-2016
Table 3.6 Other Pre-Filled Syringes: World Revenue Forecast, 2017-2022
Table 3.7 Overall World Pre-Filled Syringe Revenue Forecast, 2011-2016
Table 3.8 Overall World Pre-Filled Syringe Revenue Forecast, 2017-2022
Table 3.9 Pre-Filled Syringe Submarkets: World Revenue Forecasts, 2011-2016
Table 3.10 Pre-Filled Syringe Submarkets: World Revenue Forecasts, 2017-2022
Table 3.11 Leading Pre-Filled Syringe National Revenue Forecasts, 2011-2022
Table 4.1 Leading Product Classes Driving the Pre-Filled Syringes Market, 2011
Table 4.2 Some Currently Marketed Monoclonal Antibodies, 2012
Table 4.3 Monoclonal Antibodies Market: World Revenue Forecast, 2011-2016
Table 4.4 Monoclonal Antibodies Market: World Revenue Forecast, 2017-2022
Table 4.5 Insulins Market: World Revenue Forecast, 2011-2016
Table 4.6 Insulins Market: World Revenue Forecast, 2017-2022
Table 4.7 Erythropoietins Market: World Revenue Forecast, 2011-2016
Table 4.8 Erythropoietins Market: World Revenue Forecast, 2017-2022
Table 4.9 Some Currently Marketed Interferon Drugs, 2012
Table 4.10 Interferons Market: World Revenue Forecast, 2011-2016
Table 4.11 Interferons Market: World Revenue Forecast, 2017-2022
Table 4.12 G-CSF Market: World Revenue Forecast, 2011-2016
Table 4.13 G-CSF Market: World Revenue Forecast, 2017-2022
Table 4.14 Some Currently Marketed Recombinant Coagulation Factors, 2012
Table 4.15 Recombinant Coagulations Factors Market: World Revenue Forecast, 2011-2016
Table 4.16 Recombinant Coagulations Factors Market: World Revenue Forecast, 2017-2022
Table 4.17 Some Marketed Human Growth Hormones, 2012
Table 4.18 Some Currently Marketed Pre-Filled Immunosuppressants Products, 2012
Table 4.19 Other Therapeutic Proteins Market: World Revenue Forecast, 2011-2016
Table 4.20 Other Therapeutic Proteins Market: World Revenue Forecast, 2017-2022
Table 4.21 Some Currently Marketed Biosimilar Drugs, 2012
Table 4.22 Biosimilars Market: World Revenue Forecast, 2011-2016
Table 4.23 Biosimilars Market: World Revenue Forecast, 2017-2022
Table 4.24 Some Currently Marketed Vaccines, 2012
Table 4.25 Overall Vaccines Market: World Revenue Forecast, 2011-2016
Table 4.26 Overall Vaccines Market: World Revenue Forecast, 2017-2022
Table 5.1 Anti-Diabetic Agents Available in Pre-Filled Syringe Format, 2012
Table 5.2 Lantus: World Revenue Forecast, 2011-2016
Table 5.3 Lantus: World Revenue Forecast, 2017-2022
Table 5.4 Humalog: World Revenue Forecast, 2011-2016
Table 5.5 Humalog: World Revenue Forecast, 2017-2022
Table 5.6 NovoRapid: World Revenue Forecast, 2011-2016
Table 5.7 NovoRapid: World Revenue Forecast, 2017-2022
Table 5.8 NovoMix/NovoLog: World Revenue Forecast, 2011-2016
Table 5.9 NovoMix/NovoLog: World Revenue Forecast, 2017-2022
Table 5.10 Levemir: World Revenue Forecast, 2011-2016
Table 5.11 Levemir: World Revenue Forecast, 2017-2022
Table 5.12 Actraphane HM: World Revenue Forecast, 2011-2016
Table 5.13 Actraphane HM: World Revenue Forecast, 2017-2022
Table 5.14 Byetta: World Revenue Forecast, 2011-2016
Table 5.15 Byetta: World Revenue Forecast, 2017-2022
Table 5.16 Humira: World Revenue Forecast, 2011-2016
Table 5.17 Humira: World Revenue Forecast, 2017-2022
Table 5.18 Enbrel: World Revenue Forecast, 2011-2016
Table 5.19 Enbrel: World Revenue Forecast, 2017-2022
Table 5.20 Neulasta: World Revenue Forecast, 2011-2016
Table 5.21 Neulasta: World Revenue Forecast, 2017-2022
Table 5.22 Avonex: World Revenue Forecast, 2011-2016
Table 5.23 Avonex: World Revenue Forecast, 2017-2022
Table 5.24 Rebif: World Revenue Forecast, 2011-2016
Table 5.25 Rebif: World Revenue Forecast, 2017-2022
Table 5.26 Copaxone: World Revenue Forecast, 2011-2016
Table 5.27 Copaxone: World Revenue Forecast, 2017-2022
Table 5.28 Cimzia: World Revenue Forecast, 2011-2016
Table 5.29 Cimzia: World Revenue Forecast, 2017-2022
Table 5.30 Some Leading Pre-Filled Syringe Vaccine Products, 2012
Table 6.1 Leading Companies in the Pre-Filled Syringes Market, 2012
Table 6.2 BD: Company Revenue, 2006-2011
Table 6.3 BD Medical: Revenue by Segment, 2009-2011
Table 6.4 SCHOTT: Revenue 2008-2010
Table 6.5 Ypsomed: Revenue by Segment, 2009-2011
Table 6.6 Ypsomed: Half-Year Revenue by Segment, 2011 & 2012
Table 6.7 Gerresheimer: Revenue by Division, 2009 & 2010
Table 6.8 Unilife: Revenue by Segment, 2009-2011
Table 6.9 Leading Companies Providing Aseptic Pre-Filled Syringes and Sterile Syringe Filling Services, 2012
Table 6.10 Leading Companies Providing Syringe Filling Machines and Related Equipment, 2012
Table 7.1 Pre-Filled Syringes Market: STEP Analysis, 2012-2022
Table 7.2 SWOT Analysis of World Pre-Filled Syringes Market: Strengths, 2012-2022
Table 7.3 SWOT Analysis of World Pre-Filled Syringes Market: Weaknesses, 2012-2022
Table 7.4 SWOT Analysis of World Pre-Filled Syringes Market: Opportunities and Threats, 2012-2022
Table 7.5 Risk of Infection Following Needle Stick Incident, 2012
Table 7.6 Examples of Leachables Impacting on Safety and Product Quality
Table 9.1 Pre-Filled Syringes: World Unit Sales Forecast, 2011, 2013, 2015, 2018, 2020 and 2022
Table 9.2 Pre-Filled Syringes: Overall World Revenue Forecast and Market Breakdown, 2011, 2013, 2015, 2018, 2020 and 2022
LIST OF FIGURES
Figure 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2011-2016
Figure 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2017-2022
Figure 3.3 Pen Systems & Autoinjectors: World Revenue Forecast, 2011-2016
Figure 3.4 Pen Systems & Autoinjectors: World Sales Forecast, 2017-2022
Figure 3.5 Other Pre-Filled Syringes: World Sales Forecast, 2011-2016
Figure 3.6 Other Pre-Filled Syringes: World Sales Forecast, 2017-2022
Figure 3.7 Overall World Pre-Filled Syringe Sales Forecast, 2011-2016
Figure 3.8 Overall World Pre-Filled Syringe Sales Forecast, 2017-2022
Figure 3.9 US and Other Leading Pre-Filled Syringe Market Forecasts, 2011-2022
Figure 3.10 Leading Pre-Filled Syringe Market Forecasts (Lower Range), 2011-2022
Figure 3.11 Pre-Filled Syringe Revenue Shares of Leading National Markets, 2011
Figure 3.12 Pre-Filled Syringe Revenue Shares of Leading National Markets, 2016
Figure 3.13 Pre-Filled Syringe Revenue Shares of Leading National Markets, 2019
Figure 3.14 Pre-Filled Syringe Revenue Shares of Leading National Markets, 2022
Figure 4.1 Monoclonal Antibodies Market: World Revenue Forecast, 2011-2022
Figure 4.2 Insulins Market: World Revenue Forecast, 2011-2022
Figure 4.3 Erythropoietins Market: World Revenue Forecast, 2011-2022
Figure 4.4 Interferons Market: World Revenue Forecast, 2011-2022
Figure 4.5 G-CSF Market: World Revenue Forecast, 2011-2022
Figure 4.6 Recombinant Coagulation Factors Market: World Revenue Forecast, 2011-2022
Figure 4.7 Other Therapeutic Proteins Market: World Revenue Forecast, 2011-2022
Figure 4.8 Biosimilars Market: World Revenue Forecast, 2011-2022
Figure 4.9 Overall Vaccines Market: World Revenue Forecast, 2011-2022
Figure 5.1 Lantus: World Revenue Forecast, 2011-2022
Figure 5.2 Humalog: World Revenue Forecast, 2011-2022
Figure 5.3 NovoRapid: World Revenue Forecast, 2011-2022
Figure 5.4 NovoMix/NovoLog: World Revenue Forecast, 2011-2022
Figure 5.5 Levemir: World Revenue Forecast, 2011-2022
Figure 5.6 Actraphane HM: World Revenue Forecast, 2011-2022
Figure 5.7 Byetta: World Revenue Forecast, 2011-2022
Figure 5.8 Humira: World Revenue Forecast, 2011-2022
Figure 5.9 Enbrel: World Revenue Forecast, 2011-2022
Figure 5.10 Neulasta: World Revenue Forecast, 2011-2022
Figure 5.11 Avonex: World Revenue Forecast, 2011-2022
Figure 5.12 Rebif: World Revenue Forecast, 2011-2022
Figure 5.13 Copaxone: World Revenue Forecast, 2011-2022
Figure 5.14 Cimzia: World Revenue Forecast, 2011-2022
Figure 6.1 BD Medical Sales Revenue Shares by Area, FY 2011
Figure 6.2 BD: Company Revenue, 2006-2011
Figure 6.3 BD Medical: Revenue by Segment, 2009-2011
Figure 6.4 SCHOTT Revenue Shares by Geographical Region, 2010-2011
Figure 6.5 SCHOTT: Revenue 2008-2010
Figure 6.6 Abbott's Net Sales Worldwide, 2007-2011
Figure 6.7 Ypsomed: Revenue by Segment, 2009-2011
Figure 6.8 Ypsomed: Half-Year Revenue by Segment, 2011 & 2012
Figure 6.9 Distribution Shares of Gerresheimer Workforce, 2011-2012
Figure 6.10 Gerresheimer Sales Shares by Division, 2011
Figure 6.11 Gerresheimer Sales Shares by Region, 2011
Figure 6.12 Gerresheimer: Revenue by Division, 2009-2010
Figure 6.13 Unilife: Revenue by Segment, 2009-2011
Figure 7.1 Preference for Pre-Filled Syringes by Healthcare Professionals, 1995-1999
Figure 7.2 Pattern of Sharps Injury to Healthcare Workers, 1995-1999
Figure 9.1 Pre-Filled Syringes Market: Revenue Shares by Main Submarket, 2011
Figure 9.2 Pre-Filled Syringes: World Revenue and Unit Sales Forecasts, 2011, 2013, 2015, 2018, 2020 and 2022
COMPANIES LISTED
Abbott Laboratories
Albert David
Alkermes
Alshifa Medical Syringes Manufacturing Company
Althea Technologies
Amgen
Amylin Pharmaceuticals
Astellas Pharma
AstraZeneca
Avitro
Avrio Biopharmaceuticals
B. Braun Medical
Baccinex
Battelle Medical Device Solutions
Baxter BioPharma Solutions
Baxter International
Bayer
BD Biosciences
BD Healthcare Consulting & Services (BDHCS)
BD Pharmaceutical Systems
Becton, Dickinson and Company
Berna Biotech
BioConnection
Biogen Idec
Bioject Medical Technologies
Biopartners
Boston Scientific
C. R. Bard
Cambridge Antibody Technology (now a part of AstraZeneca)
Cambridge Consultants
Cangene BioPharma
Catalent Pharma Solutions
Centers for Disease Control and Prevention (CDC) [US]
Centocor Ortho Biotech
Ceutical Labs
Chugai Pharmaceutical (a subsidiary of Roche Holding AG.)
Coeur
Covidien
Creapharm SAS
CSL Behring
CSL Biotherapies
CT Arzneimettel
Daikyo Seiko
DALI Medical Devices
Dalton Chemical Laboratories
Disetronic Group
Disetronic Holding
Dong-A
Dongbao
E. R. Squibb & Sons
Eisai
Elcam Medical
Eli Lilly
European Medicines Agency (EMEA/EMA)
European Society for Medical Oncology
Flamel Technologies
EMD Serono
Food and Drug Administration (FDA) [US]
Fresenius Kabi Product Partnering
Gate Pharmaceuticals
Genentech
GeneScience Pharmaceutical Co.
Genzyme
Gerresheimer
GlaxoSmithKline
GP Pharm
Henke-Sass Wolf
Hindustan Syringes and Medical Devices (HMD)
Hi-Tech Medical Products
Hospira
Human Genome Sciences
Hyaluron Contract Manufacturing (HCM)
Immunex
Insulet Corp
Intas Biopharmaceuticals
International Medication Systems
JHP Pharmaceuticals
Johnson & Johnson
Jubilant HollisterStier Contract Manufacturing
LG Life Sciences
Life-Shield Products
Medex
Merck & Co.
Merck Serono
Merit Medical Systems
MG Sterile Products
MGlas
Milestone Scientific
Ministry for Health, Labor and Welfare [Japan]
Mycoscience
National Health Service (NHS) [UK]
NextPharma Technologies
Novartis
Novo Nordisk
Nycomed
Nycomed Contract Services Austria
Occupational Safety and Health Administration (OSHA) [US]
ONCOTEC Pharma Produktion
Organon Teknika
Otsuka Pharmaceutical
Owen Mumford
Patheon
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Plas-Pak Industries
PRC State Food and Drug Administration [China]
Prima Pharm
Protalix Biotherapeutics
PYRAMID Laboratories
Ratiopharm
Retractable Technologies
Revolutions Medical Corporation
Roche
ROVI
Royal College of Nursing (RCN) [UK]
Safety Syringes
Sandoz
Sanofi (previously sanofi-aventis)
Sanofi Pasteur
Schering-Plough
SCHOTT
SCM Pharma
Shanghai Celgen Bio-Pharmaceutical Co.
Simponi
Sirton Pharmaceuticals
Smiths Medical International
Solvay Injectables
Specialised Health Products International
Star Syringe
State Food and Drug Administration [China]
Takeda Pharmaceutical Company
Talecris Biotherapeutics
Terumo Medical Corporation
Teva Pharmaceutical Industries
The Research Foundation for Microbial Diseases of Osaka University (BIKEN)
Therapure Biopharma
Tonghua Dongbao Pharmaceutical Co.
UCB
UltiMed
Unilife Medical Solutions
Vetter Pharma International
Vetter Pharma-Fertigung
Vita Needle Company
West Pharmaceutical Services
Wockhardt Contract Manufacturing
World Health Organization (WHO)
Wuxi Yushou Medical Appliances Co.
Wyeth (now part of Pfizer)
Ypsomed
Figure 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2011-2016
Figure 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2017-2022
Figure 3.3 Pen Systems & Autoinjectors: World Revenue Forecast, 2011-2016
Figure 3.4 Pen Systems & Autoinjectors: World Sales Forecast, 2017-2022
Figure 3.5 Other Pre-Filled Syringes: World Sales Forecast, 2011-2016
Figure 3.6 Other Pre-Filled Syringes: World Sales Forecast, 2017-2022
Figure 3.7 Overall World Pre-Filled Syringe Sales Forecast, 2011-2016
Figure 3.8 Overall World Pre-Filled Syringe Sales Forecast, 2017-2022
Figure 3.9 US and Other Leading Pre-Filled Syringe Market Forecasts, 2011-2022
Figure 3.10 Leading Pre-Filled Syringe Market Forecasts (Lower Range), 2011-2022
Figure 3.11 Pre-Filled Syringe Revenue Shares of Leading National Markets, 2011
Figure 3.12 Pre-Filled Syringe Revenue Shares of Leading National Markets, 2016
Figure 3.13 Pre-Filled Syringe Revenue Shares of Leading National Markets, 2019
Figure 3.14 Pre-Filled Syringe Revenue Shares of Leading National Markets, 2022
Figure 4.1 Monoclonal Antibodies Market: World Revenue Forecast, 2011-2022
Figure 4.2 Insulins Market: World Revenue Forecast, 2011-2022
Figure 4.3 Erythropoietins Market: World Revenue Forecast, 2011-2022
Figure 4.4 Interferons Market: World Revenue Forecast, 2011-2022
Figure 4.5 G-CSF Market: World Revenue Forecast, 2011-2022
Figure 4.6 Recombinant Coagulation Factors Market: World Revenue Forecast, 2011-2022
Figure 4.7 Other Therapeutic Proteins Market: World Revenue Forecast, 2011-2022
Figure 4.8 Biosimilars Market: World Revenue Forecast, 2011-2022
Figure 4.9 Overall Vaccines Market: World Revenue Forecast, 2011-2022
Figure 5.1 Lantus: World Revenue Forecast, 2011-2022
Figure 5.2 Humalog: World Revenue Forecast, 2011-2022
Figure 5.3 NovoRapid: World Revenue Forecast, 2011-2022
Figure 5.4 NovoMix/NovoLog: World Revenue Forecast, 2011-2022
Figure 5.5 Levemir: World Revenue Forecast, 2011-2022
Figure 5.6 Actraphane HM: World Revenue Forecast, 2011-2022
Figure 5.7 Byetta: World Revenue Forecast, 2011-2022
Figure 5.8 Humira: World Revenue Forecast, 2011-2022
Figure 5.9 Enbrel: World Revenue Forecast, 2011-2022
Figure 5.10 Neulasta: World Revenue Forecast, 2011-2022
Figure 5.11 Avonex: World Revenue Forecast, 2011-2022
Figure 5.12 Rebif: World Revenue Forecast, 2011-2022
Figure 5.13 Copaxone: World Revenue Forecast, 2011-2022
Figure 5.14 Cimzia: World Revenue Forecast, 2011-2022
Figure 6.1 BD Medical Sales Revenue Shares by Area, FY 2011
Figure 6.2 BD: Company Revenue, 2006-2011
Figure 6.3 BD Medical: Revenue by Segment, 2009-2011
Figure 6.4 SCHOTT Revenue Shares by Geographical Region, 2010-2011
Figure 6.5 SCHOTT: Revenue 2008-2010
Figure 6.6 Abbott's Net Sales Worldwide, 2007-2011
Figure 6.7 Ypsomed: Revenue by Segment, 2009-2011
Figure 6.8 Ypsomed: Half-Year Revenue by Segment, 2011 & 2012
Figure 6.9 Distribution Shares of Gerresheimer Workforce, 2011-2012
Figure 6.10 Gerresheimer Sales Shares by Division, 2011
Figure 6.11 Gerresheimer Sales Shares by Region, 2011
Figure 6.12 Gerresheimer: Revenue by Division, 2009-2010
Figure 6.13 Unilife: Revenue by Segment, 2009-2011
Figure 7.1 Preference for Pre-Filled Syringes by Healthcare Professionals, 1995-1999
Figure 7.2 Pattern of Sharps Injury to Healthcare Workers, 1995-1999
Figure 9.1 Pre-Filled Syringes Market: Revenue Shares by Main Submarket, 2011
Figure 9.2 Pre-Filled Syringes: World Revenue and Unit Sales Forecasts, 2011, 2013, 2015, 2018, 2020 and 2022
COMPANIES LISTED
Abbott Laboratories
Albert David
Alkermes
Alshifa Medical Syringes Manufacturing Company
Althea Technologies
Amgen
Amylin Pharmaceuticals
Astellas Pharma
AstraZeneca
Avitro
Avrio Biopharmaceuticals
B. Braun Medical
Baccinex
Battelle Medical Device Solutions
Baxter BioPharma Solutions
Baxter International
Bayer
BD Biosciences
BD Healthcare Consulting & Services (BDHCS)
BD Pharmaceutical Systems
Becton, Dickinson and Company
Berna Biotech
BioConnection
Biogen Idec
Bioject Medical Technologies
Biopartners
Boston Scientific
C. R. Bard
Cambridge Antibody Technology (now a part of AstraZeneca)
Cambridge Consultants
Cangene BioPharma
Catalent Pharma Solutions
Centers for Disease Control and Prevention (CDC) [US]
Centocor Ortho Biotech
Ceutical Labs
Chugai Pharmaceutical (a subsidiary of Roche Holding AG.)
Coeur
Covidien
Creapharm SAS
CSL Behring
CSL Biotherapies
CT Arzneimettel
Daikyo Seiko
DALI Medical Devices
Dalton Chemical Laboratories
Disetronic Group
Disetronic Holding
Dong-A
Dongbao
E. R. Squibb & Sons
Eisai
Elcam Medical
Eli Lilly
European Medicines Agency (EMEA/EMA)
European Society for Medical Oncology
Flamel Technologies
EMD Serono
Food and Drug Administration (FDA) [US]
Fresenius Kabi Product Partnering
Gate Pharmaceuticals
Genentech
GeneScience Pharmaceutical Co.
Genzyme
Gerresheimer
GlaxoSmithKline
GP Pharm
Henke-Sass Wolf
Hindustan Syringes and Medical Devices (HMD)
Hi-Tech Medical Products
Hospira
Human Genome Sciences
Hyaluron Contract Manufacturing (HCM)
Immunex
Insulet Corp
Intas Biopharmaceuticals
International Medication Systems
JHP Pharmaceuticals
Johnson & Johnson
Jubilant HollisterStier Contract Manufacturing
LG Life Sciences
Life-Shield Products
Medex
Merck & Co.
Merck Serono
Merit Medical Systems
MG Sterile Products
MGlas
Milestone Scientific
Ministry for Health, Labor and Welfare [Japan]
Mycoscience
National Health Service (NHS) [UK]
NextPharma Technologies
Novartis
Novo Nordisk
Nycomed
Nycomed Contract Services Austria
Occupational Safety and Health Administration (OSHA) [US]
ONCOTEC Pharma Produktion
Organon Teknika
Otsuka Pharmaceutical
Owen Mumford
Patheon
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Plas-Pak Industries
PRC State Food and Drug Administration [China]
Prima Pharm
Protalix Biotherapeutics
PYRAMID Laboratories
Ratiopharm
Retractable Technologies
Revolutions Medical Corporation
Roche
ROVI
Royal College of Nursing (RCN) [UK]
Safety Syringes
Sandoz
Sanofi (previously sanofi-aventis)
Sanofi Pasteur
Schering-Plough
SCHOTT
SCM Pharma
Shanghai Celgen Bio-Pharmaceutical Co.
Simponi
Sirton Pharmaceuticals
Smiths Medical International
Solvay Injectables
Specialised Health Products International
Star Syringe
State Food and Drug Administration [China]
Takeda Pharmaceutical Company
Talecris Biotherapeutics
Terumo Medical Corporation
Teva Pharmaceutical Industries
The Research Foundation for Microbial Diseases of Osaka University (BIKEN)
Therapure Biopharma
Tonghua Dongbao Pharmaceutical Co.
UCB
UltiMed
Unilife Medical Solutions
Vetter Pharma International
Vetter Pharma-Fertigung
Vita Needle Company
West Pharmaceutical Services
Wockhardt Contract Manufacturing
World Health Organization (WHO)
Wuxi Yushou Medical Appliances Co.
Wyeth (now part of Pfizer)
Ypsomed
